Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

295.51
+8.603.00%
Post-market: 295.510.00000.00%19:44 EDT
Volume:456.10K
Turnover:134.35M
Market Cap:8.23B
PE:-22.97
High:298.56
Open:290.13
Low:286.00
Close:286.91
52wk High:392.70
52wk Low:50.31
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.97
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.14
PE(LYR):-21.93

Loading ...

How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates

Simply Wall St.
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)

TIPRANKS
·
Apr 26

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Apr 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)

TIPRANKS
·
Apr 24

Praxis Precision Medicines (PRAX) Gets a Buy from LifeSci Capital

TIPRANKS
·
Apr 22

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE)

TIPRANKS
·
Apr 18

Praxis Ulixacaltamide Milestone Reframes Essential Tremor Opportunity And Valuation

Simply Wall St.
·
Apr 18

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating

MT Newswires Live
·
Apr 15

Praxis Precision NDA for Ulixacaltamide in Essential Tremor

TIPRANKS
·
Apr 15

Praxis Precision Med Price Target Maintained With a $510.00/Share by Needham

Dow Jones
·
Apr 14

Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application

Dow Jones
·
Apr 14

Praxis says FDA accepts NDA review for essential tremor drug ulixacaltamide

Reuters
·
Apr 14

Praxis Precision Medicines Inc - FDA Sets Pdufa Target Action Date of January 29, 2027 for Ulixacaltamide

THOMSON REUTERS
·
Apr 14

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide Hcl in Patients With Essential Tremor

THOMSON REUTERS
·
Apr 14

Praxis Precision Medicines: Advancing CNS Pipeline and Near-Term Data Catalysts Support Buy Rating Despite Cash Burn

TIPRANKS
·
Apr 14

Praxis reports positive Phase 3 Essential3 trial results for ulixacaltamide in essential tremor

Reuters
·
Apr 13

Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target

MT Newswires Live
·
Apr 10

Praxis Precision initiated with a Strong Buy at Raymond James

TIPRANKS
·
Apr 10

Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward

TIPRANKS
·
Apr 07

Praxis reports positive elsunersen trial in pediatric epilepsies

TIPRANKS
·
Apr 07